Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2013

01.05.2013 | General Gynecology

Sublingual versus vaginal misoprostol for cervical ripening before hysteroscopy: a randomized clinical trial

verfasst von: Fateme Davari Tanha, Shohreh Salimi, Mahsa Ghajarzadeh

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the efficacy of two routes of misoprostol (sublingual and vaginal) for cervical ripening before hysteroscopy.

Methods

One hundred and ten perimenopausal women who were referred to a tertiary hospital for surgical hysteroscopy enrolled in this double-blind randomized clinical trial. They were divided into two groups to receive 400 mg misoprostol either sublingually or vaginally 6 h before hysteroscopy. The duration of dilatation, Hegar number inserted into the cervix without resistance, and hysteroscopic and drug complications were recorded for all cases.

Results

Forty-nine women in sublingual and 51 in vaginal group participated in the study. Dilatation time was significantly lower in sublingual group (P < 0.001). Median Hegar number passed into the cervix without resistance was 5 in sublingual versus 4 in vaginal group (P = 0.002). Cramp followed by vomiting and diarrhea were the most common side effects of misoprostol in the sublingual group, while cramp followed by vomiting was the most frequent side effect in the vaginal group. Diarrhea was not reported in the vaginal group (P = 0.008).

Conclusion

Sublingual route of misoprostol could be considered as an effective medication before surgical hysteroscopy in perimenopausal women.
Literatur
1.
Zurück zum Zitat Munro MG, Jensen J, Purdon TF (1994) Narrow caliber office hysteroscope. J Am Assoc Laparosc 1:S24CrossRef Munro MG, Jensen J, Purdon TF (1994) Narrow caliber office hysteroscope. J Am Assoc Laparosc 1:S24CrossRef
2.
Zurück zum Zitat Campo R, Van Belle Y, Rombatus L, Brosens I, Gordts S (1999) Office mini-hysteroscopy. Hum Reprod Update 5:73–81PubMedCrossRef Campo R, Van Belle Y, Rombatus L, Brosens I, Gordts S (1999) Office mini-hysteroscopy. Hum Reprod Update 5:73–81PubMedCrossRef
3.
Zurück zum Zitat Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC (2000) Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 96:266–270PubMedCrossRef Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC (2000) Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 96:266–270PubMedCrossRef
4.
Zurück zum Zitat Loffer FD (1989) Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 73:16–20PubMed Loffer FD (1989) Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 73:16–20PubMed
5.
Zurück zum Zitat Goldberg AB, Greenberg MB, Darney PD (2001) Misoprostol and pregnancy. N Engl J Med 344:38–47PubMedCrossRef Goldberg AB, Greenberg MB, Darney PD (2001) Misoprostol and pregnancy. N Engl J Med 344:38–47PubMedCrossRef
6.
Zurück zum Zitat Ngai SW, Chan YM, Liu KL, Ho PC (1997) Oral misoprostol for cervical priming in non-pregnant women. Hum Reprod 12:2373–2375PubMedCrossRef Ngai SW, Chan YM, Liu KL, Ho PC (1997) Oral misoprostol for cervical priming in non-pregnant women. Hum Reprod 12:2373–2375PubMedCrossRef
7.
Zurück zum Zitat Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M (2004) Oral, rectal and vaginal pharmacokinetics of misoprotol. Obstet Gynecol 103:866–870PubMedCrossRef Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M (2004) Oral, rectal and vaginal pharmacokinetics of misoprotol. Obstet Gynecol 103:866–870PubMedCrossRef
8.
Zurück zum Zitat Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC (2002) Pharmacokinetics of different routes of administration misprostol. Hum Reprod 17:332–336PubMedCrossRef Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC (2002) Pharmacokinetics of different routes of administration misprostol. Hum Reprod 17:332–336PubMedCrossRef
9.
Zurück zum Zitat Mulayim B, Celik NY, Celik G, Bagis T, Zeyneloglu HB (2010) Sublingual misoprostol for cervical ripening before diagnostic hysteroscopy in premenopausal women: a randomized, double blind, placebo-controlled trial. Fertil Steril 93:2400–2404PubMedCrossRef Mulayim B, Celik NY, Celik G, Bagis T, Zeyneloglu HB (2010) Sublingual misoprostol for cervical ripening before diagnostic hysteroscopy in premenopausal women: a randomized, double blind, placebo-controlled trial. Fertil Steril 93:2400–2404PubMedCrossRef
10.
Zurück zum Zitat Bisharah M, Al-Fozan H, Tulandi T (2003) A randomized trial of sublingual misoprostol for cervical priming before hysteroscopy. J Am Assoc Gynecol Laparosc 10:390–391PubMedCrossRef Bisharah M, Al-Fozan H, Tulandi T (2003) A randomized trial of sublingual misoprostol for cervical priming before hysteroscopy. J Am Assoc Gynecol Laparosc 10:390–391PubMedCrossRef
11.
Zurück zum Zitat Preutthipan S, Herabutya Y (2006) A randomized comparison of vaginal misoprostol and dinoprostone for cervical priming in nulliparous women before operative hysteroscopy. Fertil Steril 86:990–994PubMedCrossRef Preutthipan S, Herabutya Y (2006) A randomized comparison of vaginal misoprostol and dinoprostone for cervical priming in nulliparous women before operative hysteroscopy. Fertil Steril 86:990–994PubMedCrossRef
12.
Zurück zum Zitat Fernandez H, Alby JD, Tournoux C, Chauveaud-Lambling A, DeTayrac R, Frydman R et al (2004) Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a doubleblind, placebo-controlled trial with three dose regimens. Hum Reprod 19:1618–1621PubMedCrossRef Fernandez H, Alby JD, Tournoux C, Chauveaud-Lambling A, DeTayrac R, Frydman R et al (2004) Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a doubleblind, placebo-controlled trial with three dose regimens. Hum Reprod 19:1618–1621PubMedCrossRef
13.
Zurück zum Zitat Sordia-Hernandez LH, Rosales-Tristan E, Vazquez-Mendez J, Merino M, Iglesias JL, Garza-Leal JG, Morales A (2011) Effectiveness of misoprostol for office hysteroscopy without anesthesia in infertile patients. Obstet Gynecol 95:759–761 Sordia-Hernandez LH, Rosales-Tristan E, Vazquez-Mendez J, Merino M, Iglesias JL, Garza-Leal JG, Morales A (2011) Effectiveness of misoprostol for office hysteroscopy without anesthesia in infertile patients. Obstet Gynecol 95:759–761
14.
Zurück zum Zitat Choksuchat C, Cheewadhanaraks S, Getpook C, Wootipoom V, Dhanavoravibul K (2006) Misoprostol for cervical ripening in non-pregnant women: a randomized double-blind controlled trial of oral versus vaginal regimens. Hum Reprod 21:2167–2170PubMedCrossRef Choksuchat C, Cheewadhanaraks S, Getpook C, Wootipoom V, Dhanavoravibul K (2006) Misoprostol for cervical ripening in non-pregnant women: a randomized double-blind controlled trial of oral versus vaginal regimens. Hum Reprod 21:2167–2170PubMedCrossRef
15.
Zurück zum Zitat Saxena P, Salhan S, Sarda N (2004) Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions. Hum Reprod 19:1–4CrossRef Saxena P, Salhan S, Sarda N (2004) Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions. Hum Reprod 19:1–4CrossRef
16.
Zurück zum Zitat Tang OS, Gemzell-Danielsson K, Ho PC (2007) Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99(Suppl 2):S160–S167PubMedCrossRef Tang OS, Gemzell-Danielsson K, Ho PC (2007) Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99(Suppl 2):S160–S167PubMedCrossRef
Metadaten
Titel
Sublingual versus vaginal misoprostol for cervical ripening before hysteroscopy: a randomized clinical trial
verfasst von
Fateme Davari Tanha
Shohreh Salimi
Mahsa Ghajarzadeh
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2652-4

Weitere Artikel der Ausgabe 5/2013

Archives of Gynecology and Obstetrics 5/2013 Zur Ausgabe

Letter to the Editor

A lost LNG-IUP in the bladder

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.